Guggenheim Lifts Tenet Healthcare (THC) Price Target to $283

Tenet Healthcare Corporation (NYSE:THC) is one of the 11 Best Stocks You’ll Wish You Bought Sooner.

Guggenheim Lifts Tenet Healthcare (THC) Price Target to $283

On March 12, 2026, Guggenheim increased the price target on Tenet Healthcare Corporation (NYSE:THC) from $271 to $283 and kept a Buy rating on the stock. In addition to the 90% return reported by the company, the firm identifies a few more reasons that validate its price target adjustment. This includes the analyst’s description of the first quarter as an “easy set-up” due to conservative guidance. The firm also views the projected 10% core EBITDA growth for 2026 as a manageable hurdle when compared to Tenet Healthcare Corporation (NYSE:THC)’s historical outlook or expectations.

In a separate event that day, Mizuho raised its price target on Tenet Healthcare Corporation (NYSE:THC) from $235 to $265. The firm maintained its Outperform rating on the company’s stock. This update follows the company’s Q4 report. The firm’s analyst anticipates the company will benefit from a positive demographic shift toward an aging population and a focus on higher-acuity surgeries.

Founded in 1969, Tenet Healthcare Corporation (NYSE:THC) is a diversified healthcare services company. Based in Texas, the company operates through the Hospital Operations and Ambulatory Care segments.

While we acknowledge the risk and potential of THC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than THC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Diagnostics and Research Stocks to Buy According to Analysts and 15 Set-It-and-Forget-It Stocks to Buy in 2026

Disclosure: None.  Follow Insider Monkey on Google News.